Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumorsBeate Schultheis, Dirk Strumberg, Ansgar Santel, et al.Anticancer Research|July 24, 2010
A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancerJoachim Drevs, Michael Medinger, Klaus Mross, et al.Investigational New Drugs|October 13, 2011
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumoursTanja Trarbach, Beate Schultheis, Thomas C Gauler, et al.European Journal of Cancer (Oxford, England : 1990)|June 9, 2005
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumoursKlaus Mross, Joachim Drevs, Marianne Müller, et al.Cancer Research|July 19, 2002
PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imagingJoachim Drevs, Ralph Müller-Driver, Christine Wittig, et al.Journal of Medicinal Chemistry|December 3, 2002
Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compoundFelix Kratz, André Warnecke, Karin Scheuermann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumorsJoachim Drevs, Patrizia Siegert, Michael Medinger, et al.Cancer Chemotherapy and Pharmacology|September 21, 2005
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastasesLucy Lee, Sunil Sharma, Bruno Morgan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumorsMarlies H G Langenberg, Carla M L van Herpen, Johann De Bono, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2003
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studiesBruno Morgan, Anne L Thomas, Joachim Drevs, et al.Pageof 4